poor metabolizer

poor metabolizer

Pharmacology A person who metabolizes a probe drug–the rate of which is related to the metabolizing cytochrome P-450 enzyme–slower than others; a person can be a PM of one probe drug, and an extensive metabolizer of another. See Probe drug. Cf Extensive metabolizer.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Even when handed information on whether each clopidogrel-treated patient was a poor metabolizer of the drug, treating physicians usually did not switch them to a different antiplatelet drug, ticagrelor, that would be fully effective despite the patient's reduced-metabolizer status.
The findings of this case represent therapeutic failure of primaquine due to an allele mutation of CYP2D6 rendering the individual a poor metabolizer. While primaquine remains the therapeutic treatment for P.
Genotyping revealed the subject has CYP2D6 (*4/* 5; 1 gene copy) and CYP2C19 (*2/*2) which corresponded to poor metabolizer phenotype for both enzymes.
Currently in the USA, patients with a poor metabolizer phenotype (*2/*2, *2/*3, and *3/*3) are advised to use drugs such as prasugrel and ticagrelor [17]; however, in Chile, information regarding the prevalence of CYP2C19 polymorphisms is still lacking.
The activity of CYP2D6 is largely determined by genetic variability and common sequence variants exist in human populations that lead to poor metabolizer (PM) phenotypes [72].
Four phenotypic categories have been assigned to individuals according to enzyme function: poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM), and ultra-fast metabolizer (10,11).
When patients undergo pharmacogenetic testing, they are categorized into one of four phenotypes: ultra-rapid metabolizer (UM), extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM).
([section]) BMI, body mass index; ([parallel]) EM, extensive metabolizer; ([paragraph]) PM, poor metabolizer; (a) one patient in RA group refused the drug sensitivity test; (b) four patients (two in RAL group and two in RA group) refused the analysis of CYP2C19 polymorphism; * unpaired f-test; ** chi-square test.
The traditional assignment of phenotype is as follows: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM), and ultrarapid metabolizer (UM).
It has been shown that about 3% of Caucasians express the poor metabolizer phenotypes S-mephenytoin, however literature review in this regards shows slight differences.